GlassScriptPhysician profile
Rachel Epstein
NPI 1164863353
$6,409.30
in general payments reported to CMS, 2019-2025
28 companies · $770 in 2025
The $770 reported for 2025 was more than what a typical Cornea and External Diseases Specialist provider received nationally (typical 2025 total: $477).
See the full distribution for Cornea and External Diseases Specialist
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,031 · 2020: $1,894 · 2021: $168 · 2022: $389 · 2023: $462 · 2024: $695 · 2025: $770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,927.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,926.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,216.86 | 2019-2025 | Centurion, Clareon, Acrysof Iq Panoptix Uv Iol |
| Recordati_rare_diseases_inc. | $999.89 | 2020 | |
| Dompe US, INC. | $498.10 | 2019-2022 | |
| Glaukos Corporation | $442.30 | 2023-2025 | Idosetr, Istent Infinite, Photrexa Viscous and Photrexa |
| Carl Zeiss Meditec, INC. | $400.00 | 2020 | |
| Harrow Eye, LLC | $244.29 | 2024-2025 | Vevye |
| Novartis Pharmaceuticals Corporation | $230.70 | 2019-2023 | |
| Staar Surgical Company | $209.44 | 2019 | |
| Sun Pharmaceutical Industries INC. | $162.69 | 2020-2023 | Cequa |
| Amgen INC. | $132.82 | 2025 | Tepezza |
| Ocular Therapeutix, INC. | $114.89 | 2019-2021 | |
| Biotissue Holdings INC. | $112.16 | 2021-2022 | |
| The Cameron-Ehlen Group, INC. | $97.19 | 2019-2020 | |
| Eyevance Pharmaceuticals LLC | $74.88 | 2019-2021 | |
| Horizon Therapeutics Plc | $64.72 | 2022-2023 | Tepezza |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $55.97 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $54.89 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $48.92 | 2024 | Xdemvy |
| Bausch & Lomb Americas INC. | $44.81 | 2024-2025 | Lotemax Sm, Zylet, Prolensa |
| Kala Pharmaceuticals, INC. | $29.18 | 2020 | |
| Quidel Corporation | $28.67 | 2020 | |
| Rxsight INC | $25.53 | 2024 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Hologic Sales and Service, LLC | $22.89 | 2024 | Coolseal Generator |
| Shire North American Group INC | $22.65 | 2019 | |
| Abbvie INC. | $20.97 | 2025 | |
| Mallinckrodt Hospital Products INC. | $18.75 | 2024 | Acthar |
| Johnson & Johnson Surgical Vision, INC. | $18.39 | 2022 | |
| New World Medical,INC. | $16.75 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Epstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.